10 Under-the-Radar Stocks with Massive Upside for 2025

4. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Upside Potential: 57.29%

Stock Price as of January 18: $61.77

Number of Hedge Fund Investors: 54

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a biopharmaceutical company specializing in treatments for rare genetic diseases. The company’s portfolio includes a robust portfolio of commercial products and a strong pipeline of potential therapies across various therapeutic areas, including skeletal conditions, enzyme therapies, and gene therapy.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is expanding its portfolio through the development of new therapies and the exploration of novel indications for existing products. The company recently started the CANOPY clinical program to evaluate and expand the potential of VOXZOGO, a drug for the treatment of achondroplasia, in other genetic skeletal conditions such as hypochondroplasia, idiopathic short stature, Noonan syndrome, Turner syndrome, and SHOX deficiency. This strategic focus on broadening the therapeutic applications of VOXZOGO aims to enhance the company’s leadership in the skeletal conditions market. The Phase 3 study for VOXZOGO in hypochondroplasia is also on track, with pivotal data expected in 2026 and a potential approval in 2027.

Furthermore, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is strengthening its global commercial capabilities. The company has established a strong presence in key markets and is actively expanding into new geographies, particularly in regions outside the U.S. where approximately 90% of the global achondroplasia total addressable patient population resides.